Composition combination containing enriched hill shaddock oil
US-2024325485-A1 · Oct 3, 2024 · US
Methods of treating or alleviating mental disorders and associated symptoms
US11197840B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11197840-B2 |
| Application number | US-201615780913-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 2, 2016 |
| Priority date | Dec 4, 2015 |
| Publication date | Dec 14, 2021 |
| Grant date | Dec 14, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive compulsive disorder, anxiety disorder or a condition characterised by one or more symptoms of a obsessive compulsive disorder or an anxiety disorder.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of a repetitive behavioral pattern in a subject having obsessive compulsive disorder, comprising administering to a mammal in need thereof an effective amount of 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , comprising administering an effective amount of trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , comprising administering an effective amount of cis 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , comprising administering an effective amount of a racemic mixture of trans and cis 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salts thereof. 5. The method of claim 1 , wherein the 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is administered as a composition. 6. The method of claim 5 , wherein the composition comprises royal jelly, an extract of royal jelly, or a composition derived from royal jelly. 7. The method of claim 1 , wherein the effective amount of 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is in the range of 0.01 to 6000 mg/day, 0.1 to 5000 mg/day, 1 to 4000 mg/day, 10 to 3000 mg/day, 100 to 2000 mg/day, or 500 to 1500 mg/day. 8. The method of claim 1 , wherein the effective amount of 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is selected from the group consisting of 0.5 mg/day, 1 mg/day, 5 mg/day, 10 mg/day, 50 mg/day, 100 mg/day, 250 mg/day, 500 mg/day, 750 mg/day, 1000 mg/day, 1500 mg/day and 2000 mg/day. 9. The method of claim 1 , wherein the mammal is a human.
Assignees
Inventors
Classifications
- A61K31/201Primary
having one or two double bonds, e.g. oleic, linoleic acids · CPC title
Drugs for disorders of the nervous system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11197840B2 cover?
- The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive compulsive disorder, anxiety disorder or a condition characterised by one or more symptoms of a obsessive compulsive disorder or an anxiety disorder.
- Who is the assignee on this patent?
- The Florey Inst Of Neuroscience And Mental Health, Univ Deakin
- What technology area does this patent fall under?
- Primary CPC classification A61K31/201. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).